Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target By Benzinga Newsdesk March 1, 7:17 AM HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $57 price target. BCYC
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target By Benzinga Newsdesk March 1, 7:15 AM HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $38 price target. IOVA
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $33 Price Target By Benzinga Newsdesk March 1, 7:11 AM HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $33 price target. SNDX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $24 Price Target By Benzinga Newsdesk March 1, 7:09 AM HC Wainwright & Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:TGTX) with a Buy and maintains $24 price target. TGTX
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Integra Resources, Maintains $4 Price Target By Benzinga Newsdesk March 1, 7:07 AM HC Wainwright & Co. analyst Heiko Ihle reiterates Integra Resources (AMEX:ITRG) with a Buy and maintains $4 price target. ITRG
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Cytokinetics, Maintains $58 Price Target By Benzinga Newsdesk March 1, 6:51 AM Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $58 price target. CYTK
Read More 1 minute read Analyst Ratings News Price Target Reiteration Telsey Advisory Group Reiterates Market Perform on Chico’s FAS, Maintains $6 Price Target By Benzinga Newsdesk March 1, 6:41 AM Telsey Advisory Group analyst Dana Telsey reiterates Chico's FAS (NYSE:CHS) with a Market Perform and maintains $6 price target. CHS
Read More 1 minute read Analyst Ratings News Price Target Reiteration Tech Trading Ideas MKS Instruments Analysts Await Elaboration On Ransomware Impact Post Q4 Results By Anusuya Lahiri February 28, 3:32 PM Benchmark analyst Mark Miller had a Hold rating on MKS Instruments, Inc (NASDAQ:MKSI). For its 4Q22, MKS reported adjusted EPS of $2.00… MKSI
Read More 1 minute read Analyst Color Analyst Ratings Earnings General Guidance Health Care Movers News Price Target Reiteration Small Cap Trading Ideas Analysts Remain Bullish On SI-BONE, Forecast Q4’s Strength To Continue In 2023 By Vandana Singh February 28, 3:13 PM SI-BONE Inc (NASDAQ:SIBN) reported a Q4 EPS loss of $(0.32), beating the consensus of $(0.40) and sales of $31.95 million,… SIBN
Read More 1 minute read Analyst Color Analyst Ratings General Markets News Price Target Reiteration Small Cap Big Lots To Have Weak Q4 Results Given Current Consumer Spending Trend, Says Analyst By Shivani Kumaresan February 28, 2:46 PM Telsey Advisory Group analyst Joseph Feldman reiterated a Market Perform rating on the shares of Big Lots Inc (NYSE:BIG) and lowered the… BIG